On Tuesday, Merck & Co., Inc. (NYSE:MRK)’s shares inclined 0.44% to $52.10.
Merck (MRK), known as MSD outside Canada and the United States , declared results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy contrast to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). In the Phase 2/3 study pembrolizumab, Merck’s anti-PD-1 (programmed death receptor-1) therapy, significantly improved overall survival (OS) contrast to chemotherapy in patients with any level of PD-L1 expression, as defined by a tumor proportion score (TPS) of 1 percent or more. The results were published in The Lancet and will be presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress.
“Because lung cancer remains one of the most common and most challenging cancers to treat, understanding the role that pembrolizumab can play in assisting patients was essential to our development program. In this study in patients with PD-L1 expression of one percent or greater, pembrolizumab demonstrably improved overall survival contrast to chemotherapy in formerly-treated patients with non-small cell lung cancer, counting both squamous and non-squamous histologies,” said Dr. Roger M. Perlmutter , president, Merck Research Laboratories.
Overall Survival Findings from KEYNOTE-010
The Phase 2/3 KEYNOTE-010 study comprised of 1,034 patients with advanced NSCLC with PD-L1 expression (TPS of 1% or more). Similar findings were shown in patients who received the FDA-approved dose of pembrolizumab (2 mg/kg every three weeks) (n=345) and an investigational dose of pembrolizumab (10 mg/kg every three weeks) (n=346). Both groups of patients who received pembrolizumab were contrast to patients who received docetaxel (n=343). PD-L1 expression was assessed by the immunohistochemistry companion diagnostic test PD-L1 IHC 22C3 PharmDx, made by Dako North America , Inc., an Agilent Technologies Company. The findings from KEYNOTE-010 are based on the final study analysis. The median follow-up was 13.1 months (IQR, 8.6-17.7).
In the total study population (all levels of PD-L1 expression), both doses of pembrolizumab studied significantly improved OS contrast with docetaxel. Specifically, pembrolizumab resulted in a 29 percent improvement in OS for the 2 mg/kg dose (HR 0.71, P=0.0008; 95% CI, 0.58-0.88) and a 39 percent improvement in OS for the 10 mg/kg dose (HR 0.61, P
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
AbbVie Inc (NYSE:ABBV)’s shares gained 2.46% to $57.58. With its recent share price change, ABBV market value has reached roughly $91.86 billion. Its most recent quarter balance sheet showed the company is standing at a 2.00 current ratio and possess -6.61 as debt to equity ratio. The company has a Profit Margin (ttm) of 12.90% and has 81.50% gross margins. The operating profit margin is 22.90%. The stock’s performance in 1 month is -5.76% and its volatility for the same period is 2.12%.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
General Mills, Inc. (NYSE:GIS)‘s shares surged 1.71% to $58.39. The last trading range of General Mills, Inc. (NYSE:GIS) ranges between $57.41 and $58.57. The EPS of the company stands at $2.42. The 52-week range shows that the stock reached higher at $59.87 while its lower range is $47.43 in the last 52-weeks. The average volume of the company is at 3.49 million with the Outstanding Shares of 593.35 million. The market capitalization of the company is $34.06 billion. The Beta of the company stands at 0.36 with the RSI (Relative Strength Index) of 52.63.
General Mills, Inc. manufactures and markets branded consumer foods in the United States and internationally. It also supplies branded and unbranded food products to the foodservice and commercial baking industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.